Kevin Cannon, MD
Hospitalist · Wilmington, NCNPI 1700897022
Payments from drug & device makers
Across 7,076 payments — averaging $6715.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$16.8M
- Regeneron$11.9M
- Novo Nordisk AS$3.7M
- Modernatx, Inc.$2.6M
- Bavarian Nordic A/s$2.5M
- Johnson & Johnson$1.9M
- plus $8.1M from 24 others
Across 90 payments — averaging $478.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$31K
- Novo Nordisk AS$10K
- Regeneron$2K
- Eli Lilly$233
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 896 | $16,756,442 |
| Regeneron | 345 | $11,926,487 |
| Novo Nordisk AS | 4,061 | $3,716,050 |
| Modernatx, Inc. | 475 | $2,618,762 |
| Bavarian Nordic A/s | 112 | $2,473,303 |
| Johnson & Johnson | 30 | $1,921,761 |
| Boehringer Ingelheim | 83 | $1,774,163 |
| Biontech SE | 213 | $1,154,703 |
| Genentech, Inc. | 48 | $1,119,984 |
| GSK | 120 | $990,839 |
| AstraZeneca | 12 | $774,855 |
| Novavax Inc | 15 | $535,151 |
| Sanofi US Services Inc. | 85 | $492,779 |
| Merck | 141 | $379,543 |
| Eli Lilly | 5 | $338,744 |
| Janssen Research & Development, LLC | 6 | $171,297 |
| Lexicon Pharmaceuticals, Inc. | 10 | $98,504 |
| Hoffmann-la Roche Limited | 8 | $81,828 |
| Boehringer Ingelheim International GmbH | 209 | $53,459 |
| Astrazeneca UK Limited | 10 | $33,582 |
| Boehringer Ingelheim Canada Ltd.ltee | 52 | $30,145 |
| F. Hoffmann-la Roche AG | 5 | $29,154 |
| Pacira Therapeutics, Inc. | 2 | $21,823 |
| Boehringer Ingelheim France S.a.s. | 125 | $16,023 |
| Astellas Pharma Global Development | 1 | $8,349 |
| Eisai Inc. | 1 | $2,705 |
| Corcept Therapeutics | 2 | $149 |
| Novartis | 1 | $91 |
| Novo Nordisk | 2 | $65 |
| Philips North America LLC | 1 | $32 |
How this compares
$47,520,772 in reported general payments places this provider in the 95th percentile of 879 hospitalist providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hospitalist in Wilmington
- Emily Ray KoDurham$182K
- Mahesh ChandrasekharWinston Salem$100K
- Dwan VarnerGreenville$59K
- Adaorah OkaforWinston Salem$53K
- Honnie SpencerSalisbury$50K
- Jenna BrooksCharlotte$24K
- Ria DancelChapel Hill$13K
- Javad MonzavifarCharlotte$12K
- Bikki GautamCharlotte$12K
- Jorge PaulinoCharlotte$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.